Testing gut supplements to reduce seizures in CDKL5 disorder

This trial is testing whether alpha-lactalbumin combined with specific prebiotics and postbiotics can help reduce seizures and improve symptoms in people with CDKL5 deficiency disorder (CDD). CDD is a rare genetic condition that causes severe, hard-to-control seizures starting in infancy, along with developmental delays and other neurological challenges. The study is based on recent research showing that people with this condition have differences in their gut bacteria, and that changing the gut microbiome may help control seizures better than current medications alone.

Standard anti-seizure medications don't work well enough for most CDD patients, leaving them with ongoing seizures that interfere with development and quality of life. Recent research has discovered that the gut microbiome (the bacteria living in your digestive system) plays a role in seizure control, and CDD patients have abnormal gut bacteria composition—suggesting that this treatment approach might offer a new way to help.